Upgrade to SI Premium - Free Trial

Abbott Labs (ABT) Reiterated at Buy by Benchmark After FreeDM Trial Results

March 13, 2026 7:12 AM
Benchmark analyst Bruce D. Jackson reiterated a Buy rating and $145.00 price target on Abbott Labs (NYSE: ABT).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments